TIDMSAR
Sareum Holdings PLC
22 February 2018
(AIM: SAR) 22 February 2018
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Sareum notes that Sierra Oncology will report preclinical data
demonstrating SRA737 Synergy with PARP inhibitors at the AACR 2018
Annual Meeting
Sareum Holdings plc (AIM: SAR), the specialist cancer drug
discovery and development business, notes that Sierra Oncology, the
licence holder advancing clinical cancer candidate SRA737,
announced yesterday that it will present preclinical data
demonstrating that its Chk1 inhibitor, SRA737, synergizes with
niraparib, a poly ADP-ribose (PARP) inhibitor, in a poster at the
American Association of Cancer Research (AACR) Annual Meeting 2018
being held in Chicago, USA from 14-18 April.
PARP inhibitors prevent the repair of DNA damage and are
developed as treatments for cancer and other indications. Niraparib
is an orally active small molecule PARP inhibitor approved in the
US to treat ovarian cancer.
Sierra Oncology holds exclusive and worldwide rights for the
Chk1 inhibitor, SRA737, having licensed the programme from Sareum's
co-investment partner, the CRT Pioneer Fund in September 2016.
Dr Tim Mitchell, Chief Executive Officer of Sareum, commented:
"We are pleased to note this positive development from preclinical
studies exploring the combination of SRA737 with the PARP inhibitor
niraparib. Combining these two modalities to induce synthetic
lethality in cancer cells is a compelling proposition and we look
forward to further data and details of a potential clinical
development programme during the year."
The Press release from Sierra Oncology can be found by clicking
here
Poster Title: The Chk1 inhibitor, SRA737, synergizes with
niraparib to kill cancer cells via multiple cell death pathways
Date and Time: Monday 16 April 2018 8:00 AM - 12:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster Section
37
Poster Board Number: 11
Permanent Abstract Number: 1853
The Poster will be available on 16 April 2018 on
www.sierraoncology.com
Sierra Oncology will host a Program Update on Tuesday, 27
February from 10:00 AM - 12:00PM Eastern Time (ET) in New York, NY,
during which the senior management team will present a strategic
update on the development programme for SRA737. A live audio
webcast and archive of the presentation will be accessible through
www.sierraoncology.com.
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated Adviser and
Co-Broker)
Chris Fielding / James Sinclair-Ford 020 7220 1666
Hybridan LLP (Co-Broker)
Claire Noyce 020 3764 2341
Citigate Dewe Rogerson (Media
enquiries)
Shabnam Bashir/ Mark Swallow/
David Dible 020 7282 9571
Notes for editors:
Sareum is a drug discovery and development company delivering
targeted small molecule therapeutics, focusing on cancer and
autoimmune disease, and licensing them to pharmaceutical and
biotechnology companies at the preclinical or early clinical trials
stage.
Sareum operates an outsourced research model, working with
international collaborators and a world-wide network of research
providers. Its most advanced programme (Chk1) commenced clinical
trials in May 2016 and was licensed to NASDAQ-listed Sierra
Oncology in September 2016.
SKIL(R) (Sareum Kinase Inhibitor Library) is Sareum's drug
discovery technology platform that has so far produced the
Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease
research programmes, which are in the IND-enabling preclinical and
lead optimisation stages respectively. SKIL(R) can also generate
drug research programmes against other kinase targets.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the symbol SAR. For further
information, please visit www.sareum.co.uk
Checkpoint Kinase 1 (Chk1) and SRA737 (formerly CCT245737):
SRA737 is a highly selective, orally available, small molecule
inhibitor of Checkpoint kinase 1 (Chk1).
DNA is continuously subject to damage through a variety of
endogenous and exogenous mechanisms and, in turn, cells have
developed complex processes to resolve this DNA damage. Chk1 is a
central regulator in the DNA Damage Repair ("DDR") network of
cellular pathways that detect and repair DNA damage. Chk1 impacts
multiple cell-cycle checkpoints, temporarily inhibiting the
progression of cell replication and division in order for DNA
repair processes to be undertaken.
Malignant cells tolerate substantially greater levels of DNA
damage than would be acceptable in healthy cells. Cancer cells
survive and replicate, despite accumulating DNA damage due to
replicative stress, via an over-reliance on select components of
the DDR network including Chk1. As such, inhibition of Chk1 by
SRA737 may be synthetically lethal to cancer cells and of potential
benefit in the treatment of certain cancers.
Certain standard chemotherapeutic agents and radiotherapy also
induce DNA damage in order to kill cancer cells. There exists
potential for synergy between these standard therapies and Chk1
inhibitors such as SRA737.
SRA737737 was discovered and initially developed by scientists
in the Cancer Research UK Cancer Therapeutics Unit at The Institute
of Cancer Research (ICR) in collaboration with Sareum, with funding
provided by Cancer Research UK, the ICR and Sareum. The program was
licensed by CRT and the ICR to the CRT Pioneer Fund, a specialist
cancer investment fund established by Sixth Element Capital LLP
(6EC), Cancer Research Technology (CRT) and the European Investment
Fund (EIF) and managed by 6EC, in September 2013 and a
co-investment partnership with Sareum was formed to progress the
candidate drug through clinical trials.
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAKMGZZLMRGRZM
(END) Dow Jones Newswires
February 22, 2018 02:02 ET (07:02 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024